It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by complex lung pathogenesis affecting approximately three million people worldwide. While the molecular and cellular details of the IPF mechanism is emerging, our current understanding is centered around the lung itself. On the other hand, many human diseases are the products of complex multi-organ interactions. Hence, we postulate that a dysfunctional crosstalk of the lung with other organs plays a causative role in the onset, progression and/or complications of IPF. In this study, we employed a generative computational approach to identify such inter-organ mechanism of IPF. This approach found unexpected molecular relatedness of IPF to neoplasm, diabetes, Alzheimer’s disease, obesity, atherosclerosis, and arteriosclerosis. Furthermore, as a potential mechanism underlying this relatedness, we uncovered a putative molecular crosstalk system across the lung and the liver. In this inter-organ system, a secreted protein, kininogen 1, from hepatocytes in the liver interacts with its receptor, bradykinin receptor B1 in the lung. This ligand–receptor interaction across the liver and the lung leads to the activation of calmodulin pathways in the lung, leading to the activation of interleukin 6 and phosphoenolpyruvate carboxykinase 1 pathway across these organs. Importantly, we retrospectively identified several pre-clinical and clinical evidence supporting this inter-organ mechanism of IPF. In conclusion, such feedforward and feedback loop system across the lung and the liver provides a unique opportunity for the development of the treatment and/or diagnosis of IPF. Furthermore, the result illustrates a generative computational framework for machine-mediated synthesis of mechanisms that facilitates and complements the traditional experimental approaches in biomedical sciences.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Karydo TherapeutiX, Inc., Kyoto, Japan; Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583)
2 Karydo TherapeutiX, Inc., Kyoto, Japan (GRID:grid.418163.9); Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583)
3 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f); Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan (GRID:grid.482562.f) (ISNI:0000 0004 0629 2251)
4 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f)
5 Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan (GRID:grid.419708.3) (ISNI:0000 0004 1775 0430)
6 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (GRID:grid.482562.f); Tokushima University, Institute of Advanced Medical Sciences, Tokushima, Japan (GRID:grid.267335.6) (ISNI:0000 0001 1092 3579)
7 Karydo TherapeutiX, Inc., Kyoto, Japan (GRID:grid.267335.6); Advanced Telecommunications Research Institute International (ATR), The Thomas N. Sato BioMEC-X Laboratories, Kyoto, Japan (GRID:grid.418163.9) (ISNI:0000 0001 2291 1583); Nara Medical University, V-iCliniX Laboratory, Nara, Japan (GRID:grid.410814.8) (ISNI:0000 0004 0372 782X)